You can win by losing: p53 Mutations in rhabdomyosarcomas

Journal of Pathology

Volumn 222, Issue 2, 2010, Pages 124-128

  Post, Sean M ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cre; KRas; loxP; Metastasis; Mouse model; p53; Rhabdomyosarcoma

Indexed keywords

PROTEIN P53;

CARCINOGENESIS; GENE DELETION; GENE MUTATION; LOXP SITE; METASTASIS; NONHUMAN; NOTE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SURVIVAL; WILD TYPE; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; SOFT TISSUE TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, P53; HUMANS; MICE; MICE, MUTANT STRAINS; MUTATION; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957956145     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2757     Document Type: Note

References (27)

1. Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2, 600 patients. J Clin Oncol 2009;27:3391-3397.
2. Wolden SL, Alektiar KM. Sarcomas across the age spectrum. Semin Radiat Oncol 2010;20:45-51.
3. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
4. Linardic CM, Downie DL, Qualman S, et al. Genetic modeling of human rhabdomyosarcoma. Cancer Res 2005;65:4490-4495.
5. Stratton MR, Fisher C, Gusterson BA, et al. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res 1989;49:6324-6327.
6. Audrey P, Ewy M, Shunsuke K, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629.
7. Doyle B, Morton JP, Delaney DW, et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 2010;222:129-137.
8. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Rev Cancer 2009;9:701-713.
9. Lakso M, Sauer B, Mosinger B, et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A 1992;89:6232-6236.
10. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 1988;85:5166-5170.
11. Nagy A, Mar. L, Watts G. Creation and use of a Cre recombinase transgenic database. In Gene Knockout Protocols, (2nd edn), Wurst W, Kühn R (eds). Humana Press: New Jersey, 2008;365-378.
12. Janssen K-P, Abala M, El Marjou F, et al. Mouse models of K-rasinitiated carcinogenesis. Biochim Biophys Acta (BBA)-Rev Cancer 2005;1756:145-154.
13. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-3248.
14. Schmidt-Supprian M, Rajewsky K. Vagaries of conditional gene targeting. Nature Immunol 2007;8:665-668.
15. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-872.
16. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-860.
17. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-564.
18. Adorno M, Cordenonsi M, Montagner M, et al. A mutantp53/Smad complex opposes p63 to empower TGF[beta]-induced metastasis. Cell 2009;137:87-98.
19. Zavadil J, Bottinger EP. TGF-[beta] and epithelial-tomesenchymal transitions. Oncogene 2005;24:5764-5774.
20. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-1344.
21. Bar J, Moskovits N, Oren M. Involvement of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol 2010;21:47-54.
22. Hill R, Song Y, Cardiff RD, et al. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005;123:1001-1011.
23. Gibbons DL, Lin W, Creighton CJ, et al. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 2009;4: e5401.
24. Zheng S, El-Naggar AK, Kim ES, et al. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 2007;26:6896-6904.
25. Caulin C, Nguyen T, Lang GA, et al. An inducible mouse model for skin cancer reveals distinct roles for gain-and loss-of-function p53 mutations. J Clin Invest 2007;117:1893-1901.
26. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010;107:246-251.
27. Tsumura H, Yoshida T, Saito H, et al. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 2006;25:7673-7679.